Ensysce Biosciences Stock Buy Hold or Sell Recommendation
| ENSC Stock | USD 2.15 0.10 4.88% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Ensysce Biosciences is 'Strong Sell'. Macroaxis provides Ensysce Biosciences buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ENSC positions. Check out Ensysce Biosciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide. In addition, we conduct extensive research on individual companies such as Ensysce and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Ensysce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Execute Ensysce Biosciences Buy or Sell Advice
The Ensysce recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Ensysce Biosciences. Macroaxis does not own or have any residual interests in Ensysce Biosciences or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Ensysce Biosciences' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Ensysce Biosciences Trading Alerts and Improvement Suggestions
| Ensysce Biosciences had very high historical volatility over the last 90 days | |
| Ensysce Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| Ensysce Biosciences currently holds 301.66 K in liabilities with Debt to Equity (D/E) ratio of 6.91, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Ensysce Biosciences has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Ensysce Biosciences' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 5.21 M. Net Loss for the year was (7.99 M) with loss before overhead, payroll, taxes, and interest of (2.1 M). | |
| Ensysce Biosciences currently holds about 3.15 M in cash with (7.5 T) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1. | |
| Ensysce Biosciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Volatility clustering patterns for Ensysce Biosciences Inc. - Triple Digit Growth Focused Trade Plan Reviewed - metal.it |
Ensysce Biosciences Returns Distribution Density
The distribution of Ensysce Biosciences' historical returns is an attempt to chart the uncertainty of Ensysce Biosciences' future price movements. The chart of the probability distribution of Ensysce Biosciences daily returns describes the distribution of returns around its average expected value. We use Ensysce Biosciences price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Ensysce Biosciences returns is essential to provide solid investment advice for Ensysce Biosciences.
| Mean Return | -0.49 | Value At Risk | -7.44 | Potential Upside | 8.18 | Standard Deviation | 4.76 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Ensysce Biosciences historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Ensysce Stock Institutional Investors
| Shares | Murchinson Ltd. | 2025-03-31 | 140 K | Perceptive Advisors Llc | 2025-03-31 | 86.7 K | Adage Capital Partners Gp Llc | 2025-03-31 | 74.7 K | Sabby Management Llc | 2025-03-31 | 47 K | Fny Investment Advisers, Llc | 2025-03-31 | 3 K | Ubs Group Ag | 2025-03-31 | 1.3 K | Tower Research Capital Llc | 2025-03-31 | 441 | Blackrock Inc | 2025-03-31 | 65.0 | Bank Of America Corp | 2025-03-31 | 8.0 | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 0.0 |
Ensysce Biosciences Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (147.3K) | 12.1M | (9.1M) | (2.0M) | 2.4T | 2.5T | |
| Free Cash Flow | (1.2M) | (8.2M) | (17.9M) | (10.8M) | (7.5T) | (7.1T) | |
| Other Non Cash Items | 997.5K | 7.5M | (233.4K) | (85.8K) | (7.6T) | (7.2T) | |
| Net Income | (160.9K) | (29.1M) | (24.2M) | (10.6M) | (8.0M) | (8.4M) | |
| End Period Cash Flow | 194.2K | 12.3M | 3.1M | 1.1M | 3.5T | 3.7T | |
| Change To Inventory | (173.6K) | 441.7K | (164.9K) | (1.1M) | (1.3M) | (1.4M) |
Ensysce Biosciences Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Ensysce Biosciences or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Ensysce Biosciences' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Ensysce stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.68 | |
β | Beta against Dow Jones | 1.77 | |
σ | Overall volatility | 4.34 | |
Ir | Information ratio | -0.13 |
Ensysce Biosciences Volatility Alert
Ensysce Biosciences exhibits very low volatility with skewness of -0.33 and kurtosis of 0.99. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Ensysce Biosciences' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Ensysce Biosciences' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Ensysce Biosciences Fundamentals Vs Peers
Comparing Ensysce Biosciences' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Ensysce Biosciences' direct or indirect competition across all of the common fundamentals between Ensysce Biosciences and the related equities. This way, we can detect undervalued stocks with similar characteristics as Ensysce Biosciences or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Ensysce Biosciences' fundamental indicators could also be used in its relative valuation, which is a method of valuing Ensysce Biosciences by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Ensysce Biosciences to competition |
| Fundamentals | Ensysce Biosciences | Peer Average |
| Return On Equity | -2.22 | -0.31 |
| Return On Asset | -0.88 | -0.14 |
| Profit Margin | (1.10) % | (1.27) % |
| Operating Margin | (1.49) % | (5.51) % |
| Current Valuation | 2.06 M | 16.62 B |
| Shares Outstanding | 2.37 M | 571.82 M |
| Shares Owned By Insiders | 0.43 % | 10.09 % |
| Shares Owned By Institutions | 14.91 % | 39.21 % |
| Number Of Shares Shorted | 159.41 K | 4.71 M |
| Price To Book | 1.59 X | 9.51 X |
| Price To Sales | 0.78 X | 11.42 X |
| Revenue | 5.21 M | 9.43 B |
| Gross Profit | (2.1 M) | 27.38 B |
| EBITDA | (6.73 M) | 3.9 B |
| Net Income | (7.99 M) | 570.98 M |
| Cash And Equivalents | 3.15 M | 2.7 B |
| Cash Per Share | 0.10 X | 5.01 X |
| Total Debt | 301.66 K | 5.32 B |
| Debt To Equity | 6.91 % | 48.70 % |
| Current Ratio | 0.87 X | 2.16 X |
| Book Value Per Share | 1.85 X | 1.93 K |
| Cash Flow From Operations | (7.5 T) | 971.22 M |
| Short Ratio | 2.22 X | 4.00 X |
| Earnings Per Share | 110.31 X | 3.12 X |
| Target Price | 20.23 | |
| Number Of Employees | 7 | 18.84 K |
| Beta | 1.02 | -0.15 |
| Market Capitalization | 4.86 M | 19.03 B |
| Total Asset | 5.6 M | 29.47 B |
| Retained Earnings | (129.54 T) | 9.33 B |
| Working Capital | 3.14 M | 1.48 B |
| Net Asset | 5.6 M |
Note: Insider Trading [view details]
Ensysce Biosciences Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Ensysce . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 27170.95 | |||
| Daily Balance Of Power | 0.5263 | |||
| Rate Of Daily Change | 1.05 | |||
| Day Median Price | 2.09 | |||
| Day Typical Price | 2.11 | |||
| Price Action Indicator | 0.1 | |||
| Period Momentum Indicator | 0.1 |
About Ensysce Biosciences Buy or Sell Advice
When is the right time to buy or sell Ensysce Biosciences? Buying financial instruments such as Ensysce Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Ensysce Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run FinTech Thematic Idea Now
FinTech
High long term potential financial entities that are ranging from payment processing, investment management to commercial and investment banking. The FinTech theme has 66 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize FinTech Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Ensysce Biosciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 110.31 | Revenue Per Share | Quarterly Revenue Growth 3.317 | Return On Assets | Return On Equity |
The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.